Healthcare Providers and Services
Company Overview of A. Menarini Asia-Pacific Holdings Pte. Ltd.
A. Menarini Asia-Pacific Holdings Pte. Ltd. engages in the marketing and distribution of pharmaceutical, biotechnology, medical device, and consumer health brands in the Asia-Pacific. It operates across the entire commercial value chain, ranging from clinical development, regulatory approval, and product launch to lifecycle management with a portfolio of proprietary and partnered brands in therapeutic fields, including consumer health, dermatology, primary care, allergy/respiratory, cardiovascular, oncology/specialty care, and men's health. A. Menarini Asia-Pacific Holdings Pte. Ltd. was formerly known as Invida Holdings Private Limited and changed its name to A. Menarini Asia-Pacific Holdin...
30, Pasir Panjang Road
Mapletree Business City, 08-32
Founded in 2005
Key Executives for A. Menarini Asia-Pacific Holdings Pte. Ltd.
Chief Executive Officer and Director
Chief Financial Officer and Director
Managing Director of India
Managing Director of Indonesia
Chief Administrative Officer
Compensation as of Fiscal Year 2017.
A. Menarini Asia-Pacific Holdings Pte. Ltd. Key Developments
Menarini Group and MSD Extends Global Partnership to the Asia-Pacific Region
Jun 9 16
A. Menarini Asia-Pacific Holdings Pte Ltd. and MSD have embarked on a multi-year partnership for Menarini Asia-Pacific to assume the sales, marketing and distribution of a number of MSD’s pharmaceutical brands in Asia-Pacific since January 2016. The partnership involves six countries, namely Malaysia, Singapore, Philippines, Hong Kong, Brunei and Macao with annual sales in excess of USD 70 million that could potentially extend to other key Asia-Pacific markets. The partnership covers a portfolio of highly recognized brands among physicians and patients, ranging from Cardiology, Respiratory and Women’s Health to Central Nervous System and Dermatology. Prior to this agreement, Menarini and MSD had already developed similar partnerships in several other markets in Europe.
Menarini China Presents at ChinaBio Partnering Forum 2016, May-18-2016
Apr 13 16
Menarini China Presents at ChinaBio Partnering Forum 2016, May-18-2016 . Venue: Suzhou, China.
Mitsubishi Tanabe Pharma Corporation Signs Licensing Agreement with A. Menarini Asia-Pacific Holdings Pte Ltd for SPEDRA (Avanafil) in 10 Countries in Asia-Pacific
Feb 26 16
Mitsubishi Tanabe Pharma Corporation and A. Menarini Asia-Pacific Holdings Pte Ltd. have entered into a licensing agreement to commercialize and promote SPEDRA (avanafil). Menarini AP will receive exclusive licensing rights from Mitsubishi Tanabe Pharma Corporation to market Avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam. Menarini AP is a member of the Menarini Group. Menarini Group has already been licensed to market this product in over 40 European countries, plus Australia and New Zealand. SPEDRA (avanafil) is a new and innovative phosphodiesterase – 5 inhibitor (PDE5-i) approved by the European Commission in June 2013 for the treatment of erectile dysfunction. In the U.S., FDA approved avanafil in April 2012 for the same indication, under the trade name STENDRA.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|